Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
bullous pemphigoid epidemiology forecast

bullous-pemphigoid-epidemiology-forecast-report

SALE

Bullous Pemphigoid - Epidemiology Forecast - 2034

Published Date : 2025

Pages : 87

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

bullous pemphigoid epidemiology forecast

DelveInsight's "Bullous Pemphigoid (BP)- Epidemiology Forecast-2034" report delivers an in-depth understanding of the BP, historical and forecasted epidemiology as well as the BP market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan

Study Period: 2021-2034

Bullous Pemphigoid (BP) Understanding

The DelveInsight’s Bullous Pemphigoid epidemiology report gives a thorough understanding of the BP, which is a rare skin condition that mainly affects older people. It usually starts with an itchy, raised rash. As the condition develops, large blisters can form on the skin. It is characterized by a poor prognosis due to its high mortality rate and the tendency to relapse. The relapse rate of BP ranges from 27.87% to 53% after disease remission, while the majority of relapses occur early (within 6 months) during remission. Treatment usually helps heal the blisters and ease any itching.

Pruritus is the first symptom of bullous pemphigoid. Skin lesions may not develop for several years. Often, characteristic tense bullae develop on the skin of the trunk and in the flexural and intertriginous areas. Bullae may develop on normal-appearing skin or may be preceded by erythematous or urticarial-appearing plaques. The localized disease may occur at trauma sites, stomas, and anogenital and lower leg areas.

The diagnosis of BP is based on a combination of clinical features, positive direct immunofluorescence (IF) microscopy of perilesional skin, and the detection of specific circulating IgG anti-basement membrane autoantibodies by either indirect IF microscopy studies or by enzyme-linked immunosorbent assay (ELISA). In the majority of cases, the latter tests are sufficient for a correct diagnosis between myopathies, genetic testing remains the standard in distinguishing between disease pathology.

Bullous Pemphigoid (BP) Epidemiology

The epidemiology section provides insights about the historical and current BP patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides a historical as well as forecasted BP epidemiology scenario in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2021 to 2034.

In 2021, the total diagnosed prevalent cases of BP were approximately 132,200 in the 7MM which are expected to grow during the study period, i.e., 2021-2034.

The disease epidemiology covered in the report provides historical as well as forecasted BP epidemiology [segmented as Diagnosed prevalent cases of BP, Gender-specific diagnosed prevalent cases of BP, Age-specific diagnosed prevalent cases of BP, Severity-specific diagnosed prevalent cases of BP, and Total treated cases of BP in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2021 to 2034.

Country Wise- Bullous Pemphigoid (BP) Epidemiology

The epidemiology segment also provides the BP epidemiology data and findings across the United States, EU4 and the United Kingdom, and Japan.

KOL- Views

To keep up with the current BP patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the BP domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

Scope of the Report

The report covers the descriptive overview of BP, explaining its causes, symptoms, pathophysiology, and genetic basis.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 countries and the United Kingdom, and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of BP.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report provides the segmentation of the disease epidemiology for 7MM by Diagnosed prevalent cases of BP, Gender-specific diagnosed prevalent cases of BP, Age-specific diagnosed prevalent cases of BP, Severity-specific diagnosed prevalent cases of BP, and Total treated cases of BP in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2021 to 2034

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence BP R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for BP.
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Bullous Pemphigoid (BP) Report Key Strengths

11 Years Forecast
7MM Coverage
BP Epidemiology Segmentation

Key Questions

Epidemiology Insights:

What are the disease risk, burden, and regional/ethnic differences of BP?
What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
What is the historical BP patient pool in seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
What would be the forecasted patient pool of BP in seven major markets covering the United States, EU4 and the United Kingdom, and Japan?
Where will be the growth opportunities in the 7MM concerning the patient population about BP?
Out of all 7MM countries, which country would have the highest prevalent population of BP during the forecast period (2025-2034)?
At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

Reasons to buy

The report will help in developing business strategies by understanding trends shaping and driving the BP Disease market
To understand the future market competition in the BP Disease market
Organize sales and marketing efforts by identifying the best opportunities for BP Disease in the US, the EU4 and the UK, and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for the BP Disease market
To understand the future market competition in the BP Disease market

1. Key Insights

2. Report Introduction

3. BP Market Overview at a Glance

3.1. Market Share (%) Distribution of BP in 2021

3.2. Market Share (%) Distribution of BP in 2034

4. Executive Summary of BP

4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Types of BP

6.3. Triggering Diseases and Factors of BP

6.3.1. Drugs

6.3.2. Vaccines

6.3.3. Infections

6.3.4. Physical factors

6.3.5. Aging

6.3.6. Neurologic Diseases

6.3.7. Malignancies

6.4. Symptoms of BP

6.5. Pathogenesis of BP

6.5.1. Role of the complement system

6.5.2. Role of inflammatory cells

6.5.3. Role of proteolytic enzymes

6.5.4. Role of direct mechanisms

6.6. Biomarkers of BP

6.6.1. Markers of BP activity and severity

6.6.2. Markers of BP outcome

7. Diagnosis of BP

7.1. History

7.2. Clinical Manifestation

7.3. Histological Examination

7.4. Direct Immunopathological Tests

7.5. Indirect Immunofluorescence Tests

7.6. ELISA Tests

7.7. Differential Diagnosis

7.8. Diagnostic Algorithm of BP

7.9. Diagnostic Guidelines of BP

7.9.1. Guidelines for the management of BP initiated by the European Academy of Dermatology and Venereology (EADV)

7.9.2. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita [EBA])

7.9.2.1. Diagnostic criteria

7.9.2.2. Disease severity determination criteria

8. Treatment and Management

8.1. Systemic steroids

8.2. Topical corticosteroids

8.3. Azathioprine (AZA)

8.4. Anti-inflammatory antibiotics and nicotinamide

8.5. Methotrexate

8.6. Mycophenolate mofetil

8.7. Dapsone and sulfonamides

8.8. Intravenous immunoglobulins

8.9. Chlorambucil

8.10. Cyclophosphamide

8.11. Ciclosporin

8.12. Other treatments

8.12.1. Topical tacrolimus

8.12.2. Biologic agents

8.12.3. Plasmapheresis and immunoapheresis

8.13. Treatment Algorithm for BP

8.14. Guidelines for the Treatment of BP

8.14.1. Guidelines for the management of BP initiated by the European Academy of Dermatology and Venereology (EADV)

8.14.2. British Journal of Dermatology Guidelines for the management of BP

8.14.3. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)

9. Conclusion

10. Epidemiology and Patient Population

10.1. Key Findings

10.2. Assumptions and Rationale: The 7MM

10.3. Epidemiology Scenario in the 7MM

10.3.1. Diagnosed prevalent cases of BP in the 7MM

10.3.2. Gender-specific diagnosed prevalent cases of BP in the 7MM

10.3.3. Age-specific diagnosed prevalent cases of BP in the 7MM

10.3.4. Severity-specific diagnosed prevalent cases of BP in the 7MM

10.3.5. Total treated cases of BP in the 7MM

10.4. Epidemiology Scenario in the US

10.4.1. Diagnosed prevalent cases of BP in the US

10.4.2. Gender-specific diagnosed prevalent cases of BP in the US

10.4.3. Age-specific diagnosed prevalent cases of BP in the US

10.4.4. Severity-specific diagnosed prevalent cases of BP in the US

10.4.5. Total treated cases of BP in the US

10.5. Epidemiology Scenario in the EU4 and the UK

10.5.1. Diagnosed prevalent cases of BP in the EU4 and the UK

10.5.2. Gender-specific diagnosed prevalent cases of BP in the EU4 and the UK

10.5.3. Age-specific diagnosed prevalent cases of BP in the EU4 and the UK

10.5.4. Severity-specific diagnosed prevalent cases of BP in the EU4 and the UK

10.5.5. Total treated cases of BP in the EU4 and the UK

10.6. Epidemiology Scenario in Japan

10.6.1. Diagnosed prevalent cases of BP in Japan

10.6.2. Gender-specific diagnosed prevalent cases of BP in Japan

10.6.3. Age-specific diagnosed prevalent cases of BP in Japan

10.6.4. Severity-specific diagnosed prevalent cases of BP in Japan

10.6.5. Total treated cases of BP in Japan

11. Unmet Needs

12. Appendix

12.1. Bibliography

12.2. Acronyms and Abbreviations

12.3. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

List of Tables:

List of Tables

Table 1: Summary of BP, Market, Epidemiology, and Key Events (2021-2034)

Table 2: Types of BP

Table 3: Diagnostic Criteria for Pemphigoid (including epidermolysis bullosa acquisita)

Table 4: Disease Severity Determination Criteria for Pemphigoid (including epidermolysis bullosa acquisita)

Table 5: Summary of treatment choice

Table 6: Diagnosed Prevalent Cases of BP in the 7MM (2021-2034)

Table 7: Gender-specific Diagnosed Prevalent Cases of BP in the 7MM (2021-2034)

Table 8: Age-specific Diagnosed Prevalent Cases of BP in the 7MM (2021-2034)

Table 9: Severity-specific Diagnosed Prevalent Cases of BP in the 7MM (2021-2034)

Table 10: Total Treated Cases of BP in the 7MM (2021-2034)

Table 11: Diagnosed Prevalent Cases of BP in the US (2021-2034)

Table 12: Gender-specific Diagnosed Prevalent Cases of BP in the US (2021-2034)

Table 13: Age-specific Diagnosed Prevalent Cases of BP in the US (2021-2034)

Table 14: Severity-specific Diagnosed Prevalent Cases of BP in the US (2021-2034)

Table 15: Total Treated Cases of BP in the US (2021-2034)

Table 16: Diagnosed Prevalent Cases of BP in the EU4 and the UK (2021-2034)

Table 17: Gender-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2021-2034)

Table 18: Age-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2021-2034)

Table 19: Severity-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2021-2034)

Table 20: Total Treated Cases of BP in the EU4 and the UK (2021-2034)

Table 21: Diagnosed Prevalent Cases of BP in Japan (2021-2034)

Table 22: Gender-specific Diagnosed Prevalent Cases of BP in Japan (2021-2034)

Table 23: Age-specific Diagnosed Prevalent Cases of BP in Japan (2021-2034)

Table 24: Severity-specific Diagnosed Prevalent Cases of BP in Japan (2021-2034)

Table 25: Total Treated Cases of BP in Japan (2021-2034)

List of Figures:

List of Figures

Figure 1: Epidemiology and Market Methodology

Figure 2: Understanding of BP

Figure 3: Triggering Diseases and Factors of BP

Figure 4: Symptoms of BP

Figure 5: Pathogenesis of BP

Figure 6: Diagnostic Approach to the Patient with BP

Figure 7: Schematic diagram of an ELISA

Figure 8: Diagnostic Algorithm of BP

Figure 9: Algorithm for the Treatment of BP

Figure 10: Diagnosed Prevalent Cases of BP in the 7MM (2021-2034)

Figure 11: Gender-specific Diagnosed Prevalent Cases of BP in the 7MM (2021-2034)

Figure 12: Age-specific Diagnosed Prevalent Cases of BP in the 7MM (2021-2034)

Figure 13: Severity-specific Diagnosed Prevalent Cases of BP in the 7MM (2021-2034)

Figure 14: Total Treated Cases of BP in the 7MM (2021-2034)

Figure 15: Diagnosed Prevalent Cases of BP in the US (2021-2034)

Figure 16: Gender-specific Diagnosed Prevalent Cases of BP in the US (2021-2034)

Figure 17: Age-specific Diagnosed Prevalent Cases of BP in the US (2021-2034)

Figure 18: Severity-specific Diagnosed Prevalent Cases of BP in the US (2021-2034)

Figure 19: Total Treated Cases of BP in the US (2021-2034)

Figure 20: Diagnosed Prevalent Cases of BP in the EU4 and the UK (2021-2034)

Figure 21: Gender-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2021-2034)

Figure 22: Age-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2021-2034)

Figure 23: Severity-specific Diagnosed Prevalent Cases of BP in the EU4 and the UK (2021-2034)

Figure 24: Total Treated Cases of BP in the EU4 and the UK (2021-2034)

Figure 25: Diagnosed Prevalent Cases of BP in Japan (2021-2034)

Figure 26: Gender-specific Diagnosed Prevalent Cases of BP in Japan (2021-2034)

Figure 27: Age-specific Diagnosed Prevalent Cases of BP in Japan (2021-2034)

Figure 28: Severity-specific Diagnosed Prevalent Cases of BP in Japan (2021-2034)

Figure 29: Total Treated Cases of BP in Japan (2021-2034)

Tags:

License Type

Offer